A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Patients with Progressive Supranuclear Palsy with an Open-Label Extension
A study of safety and efficacy of IV BMS-986168 in patients with Progressive Supranuclear Palsy.
Sponsor: Biogen
Enrolling: Male and Female Patients
IRB Number: AAAR2560
U.S. Govt. ID: NCT03068468
Contact: Evelyn Dominguez-Rivera: 212 -305 -2371 / edd5@cumc.columbia.edu
Additional Study Information: The Primary objective of the study is to evaluate the efficacy of the study drug, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) after one year, and to assess the safety and tolerability of the study drug, relative to placebo.
This study is closed
Lawrence Honig, MD, PhD
Do You Qualify?
Do you have Progressive Supranuclear Palsy? Yes No
Do you have a primary caregiver? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Evelyn Dominguez-Rivera
212 -305 -2371